Keybank National Association OH Purchases 297,683 Shares of Kenvue Inc. (NYSE:KVUE)

Keybank National Association OH raised its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 6.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,973,410 shares of the company's stock after buying an additional 297,683 shares during the period. Keybank National Association OH owned approximately 0.26% of Kenvue worth $119,262,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its holdings in Kenvue by 3.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after buying an additional 8,211,748 shares during the last quarter. Vanguard Group Inc. increased its stake in Kenvue by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock valued at $4,665,908,000 after purchasing an additional 1,636,741 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in Kenvue by 12.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Kenvue by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock worth $980,989,000 after purchasing an additional 1,391,854 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in shares of Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after buying an additional 16,269,721 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several recent research reports. Barclays raised their price target on Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a report on Monday, May 12th. UBS Group lifted their price target on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Friday, May 9th. Citigroup restated a "neutral" rating on shares of Kenvue in a report on Friday, June 13th. Redburn Atlantic began coverage on Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective on the stock. Finally, Canaccord Genuity Group raised their price objective on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of "Hold" and a consensus target price of $25.33.

Kenvue Trading Down 0.4%

KVUE traded down $0.08 during mid-day trading on Wednesday, reaching $20.89. The stock had a trading volume of 18,186,686 shares, compared to its average volume of 16,119,267. The stock has a market capitalization of $40.08 billion, a P/E ratio of 37.98, a P/E/G ratio of 3.25 and a beta of 0.84. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $25.17. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. The firm's fifty day simple moving average is $22.73 and its two-hundred day simple moving average is $22.34.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same period last year, the company earned $0.28 earnings per share. The company's revenue was down 3.9% on a year-over-year basis. On average, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were given a $0.205 dividend. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.93%. Kenvue's dividend payout ratio is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.